Category Archives: Psoriasis

If you have psoriatic arthritis and work from home, its important to adjust your workspace to fit your needs. Pain and stiffness especially in the elbows and hands are common complaints, due to the repetitive motions involved in some office tasks and sitting in the same position all day. But making the right adjustments can help ease neck and lower back pain as well as joint pain and swelling that could otherwise make it hard to sit at a desk for hours.

An ergonomically correct workspace can help ease joint symptoms and reduce fatigue from spending extended periods of time in uncomfortable positions. Ergonomics is the science of fitting the task to the worker to maximize productivity while reducing discomfort, fatigue, and injury, says Natalia Ruiz, a physical therapist and certified office ergonomics evaluator with Rusk Rehabilitation at NYU Langone Health in New York City. Having an ergonomic setup ensures you work in neutral postures that reduce strain in your joints and tissues already affected by psoriatic arthritis. Therefore it can reduce your symptoms or reduce the risk of developing them [in the first place].

Proper support and good body mechanics can help prevent compensatory movement patterns that can lead to increased pain and stiffness, adds Jamie Hilker, an occupational therapist and certified hand therapist at Mayo Clinic in Rochester, Minnesota.

If you work a full-time job and require new equipment to make your home office more psoriatic arthritis friendly, talk to your employer. The Social Security Administration considers psoriatic arthritis a disability, and the Americans with Disabilities Act (ADA) requires employers to make reasonable accommodations that enable full-time employees to perform their essential job functions.

Reasonable accommodations may include physical changes to your workspace and accessible and assistive devices. That includes anything you need to be comfortable and productive at your job, such as special equipment you need. While these requirements dont always cover purchasing specific expensive equipment, your employer may be eligible for tax credits if they do supply you with accommodations.

In many cases, small adjustments to your workstation can make a big difference. Here are a few tips to help you set up a psoriatic arthritisfriendly home office.

An occupational or physical therapist who has knowledge in office ergonomics can help you design and modify your current home office space. These therapists specialize in adapting your environment to your abilities to help you better perform daily activities and reach your goals. They assess your particular setup, listen to your needs, and make recommendations based on observation and research, says Ruiz.

Hilker recommends looking for a licensed and registered occupational therapist or certified hand therapist. Ruiz suggests looking for a certified office ergonomics evaluator or board-certified practitioner of professional ergonomics.

To be covered by insurance, most evaluations require a doctors referral, says Hilker. Insurance typically covers some of the costs, but most people end up paying a portion [out of pocket], she says. Many corporate human resources departments will provide these services to their employees, Ruiz adds.

Your seated posture affects the positioning of your whole body. We can observe an increase in the stress on involved joints, such as the elbows, hands, knees, and feet when people sit in awkward positions, says Ruiz.

A comfortable chair is essential.Your workstation chair should:

Position your monitor directly in front of your face, with the top of the screen at or slightly below eye level. It should be about an arms length from you and directly behind your keyboard. (You may need to lower the monitor an inch or two if you wear bifocals).

Hilker says her psoriatic arthritis patients often say they struggle to find a comfortable position on a laptop. I often recommend getting a separate wireless keyboard in this case, she says. You can also buy an adjustable ergonomic laptop stand or a docking station with a full-size monitor to raise the height of your screen.

Your keyboard should be at a height where your elbows sit at or slightly more than 90 degrees while your wrists remain straight. If your keyboard is too high, you may want to either raise the height of your chair or buy a keyboard tray thats adjustable for both height and tilt and large enough to fit your keyboard and mouse on the same level.

Both Ruiz and Hilker recommend using an ergonomic split keyboard. It places the forearms and wrists in a more neutral position, says Hilker. She suggests trying out a few options at the store to figure out which feels most comfortable to you.

A keyboard rest may or may not keep your wrists in a more neutral position and prevent you from leaning your wrists on the edge of your desk. Just avoid mouse pads; Ruiz says theyre not great for your wrists and hands.

Once the rest of your body is in the correct position, check your feet: They should always remain firmly planted on the floor.

If your feet dont reach the ground when your chair is properly adjusted to your desk and computer equipment, place a footrest, small stool, or stack of books under your feet, suggests Ruiz.

Select a mouse that ensures your palm isnt completely flat, to avoid pressure on your wrist, suggests Ruiz. A vertical mouse (or any other mouse) that puts the hand in a slightly tilted position is a good bet.

It may also be easier for you to use a track pad instead of a mouse, as long as it reduces the stress in your hand and wrist. If you work in design, for example, where you have to constantly use a mouse, a trackpad can be a great option. If not, an ergonomic mouse can be used, says Ruiz. Some trackpads can be regulated to decrease the amount of pressure needed to activate and scroll, which can be helpful if joints are painful, adds Hilker.

Avoid any trackball mouse, Ruiz adds, since they tend to require too much motion in your thumb and fingers.

Keep objects you use a lot, such as your phone or stapler, within arms reach. If you cant comfortably reach something when youre sitting, stand up to get it.

Several other arthritis-approved assistive devices can reduce strain on the joints and help improve your symptoms and work performance, says Ruiz, including:

If you use the phone a lot for work especially if you have to take notes while talking use a headset or put your phone on speaker. This helps reduce stress in the neck and shoulders and keeps you from having to grip the phone in your hand or, worse, between your shoulder and ear.

Voice recognition apps and headsets can help decrease the amount of typing, says Hilker, which may also decrease pain.

Pay attention to your body throughout the day. If something feels tense or tight, get up, move, and stretch a bit.

Try to take a break and walk around your home or outside every 20 to 30 minutes. It doesnt have to be long: Two minutes is enough to reduce strain and get your blood flowing. Or Hilker suggests the 20-20-20 rule: Every 20 minutes, take a 20-second break and move 20 feet away from your workstation. Full-body movement is best, she says. Simply get up and walk around.

Add in a few gentle stretches that take just a minute or less. Focus on the areas that need it most: your neck, chest, lower back, forearms, and hips. Doing gentle shoulder rolls, neck movements, or low-back extensions can help reduce stiffness related to prolonged postures or repetitive motions, says Ruiz.

Sitting in awkward positions for long periods can lead to pain. For someone who has psoriatic arthritis, changing postures while working is very important to reduce stress to joints, muscles, ligaments, and tendons that can potentially generate pain, says Ruiz. Switching between sitting for 40 minutes and standing for 20 minutes is ideal, she says.

Sit-to-stand workstations are an excellent alternative to promote movement, adds Hilker.

Listen to your body, says Ruiz. Aim for comfort as much as possible, and plan ahead for rest periods during busy workdays.

Its also essential to keep work-related stress in check. Increased stress has been linked to increased pain level perception, says Ruiz. She recommends finding time for mindfulness activities, such as meditation, relaxation, and deep breathing exercises, during your day.

Continued here:
11 Ways to Make Your Home Office Psoriatic Arthritis Friendly - Everyday Health

In a study published in the National Library of Health, dermatology and diet was investigated.

The study noted: For decades, it was thought that many common dermatological conditions had no relationship to diet. Studies from recent years, however, have made it clear that diet may influence outcome.

In some cases, dietary interventions may influence the course of the skin disease, as in acne. In others, dietary change may serve as one aspect of prevention, such as in skin cancer and aging of the skin.

In others, dermatological disease may be linked to systemic disease, and dietary changes may affect health outcomes, as in psoriasis.

Numerous studies have found that a diet rich in fruits and vegetables reduces the risk of cancer.

Rhytids, sagging of skin, and loss of elasticity are all related to changes in the collagen and elastic fibres of the skin, which are themselves impacted by diet. Ingestion of sugar, in particular, can accelerate these signs of ageing, as it promotes cross-linking of collagen fibres.

The study concluded that dietary interventions have traditionally been an under appreciated aspect of dermatological therapy.

Recent research, however, has found a significant association between diet and some dermatological diseases.

See the article here:
Skin health: The best and worst foods for acne, psoriasis and skin disease - Express

It may seem like time is standing still right now, but we assure you fall has arrived. And, as usual, its brought with it a whole new set of skincare priorities as the weather shifts in many parts of the country. With the air becoming drier, temperatures falling, and winds picking up in some areas, a few small changes to your regimen can help keep your skin happy all season long. Below, three trickiest ways autumn can impact chronic skin conditions, plus how to combat them.

As the weather cools, irritation can go up, which means you might get flares of certain skin conditions. Joshua Zeichner, M.D., a board-certified dermatologist in NYC and associate professor of dermatology at the Mount Sinai Hospital says it makes sense: When the skin barrier becomes disrupted, it is more likely to become inflamed. That means dermatologists offices are flooded with complaints of psoriasis, eczema, and the like when the leaves start to turn. Here, the most common conditions that flare in the fall.

Psoriasis. This itch-inducing condition characterized by tale-tell plaques is normally better in the summer because of all the UV rays from natural sunlight, explains Sharleen St. Surin-Lord, M.D., an assistant professor of dermatology at Howard University in Washington, D.C. So when fall ushers in more indoor time, youve got to rely on those major psoriasis-curbing strategies like using moisturizer liberally throughout the day, firing up a humidifier at home, and talking with your doctor about adjusting your treatment regimen or adding ultraviolet light therapy.

Pityriasis rosea. Why this benign scaly pink rash can pop up more often on the trunk, upper legs, and arms this time of year: Pityriasis rosea is thought to be triggered by a viral infection, and since viruses are more common in the fall and winter, in some regions see more cases during that time, says Hayley Goldbach, M.D., a board-certified dermatologist and dermatologic surgeon at Brown University in Providence, RI. Home remedies include oatmeal baths and anti-itch lotions. While it is not a dangerous condition, talk to your doctor if the rash is itchy to see if medications can help with the discomfort.

Hives. Fall allergy season brings the increased risk of hives as you come in contact with itch-triggering fall staples like wool fabrics and ragweed pollen. If you get them once, an over-the-counter antihistamine will help, but if they happen frequently, Dr. Surin-Lord says to make an appointment with your derm for an Rx.

Eczema. Blame the dry fall air and scratchy scarves and sweaters for eczema flares. To help keep them at bay, look for soft cotton fabrics. And Dr. Surin-Lord recommends moisturizing with a hydrator featuring ceramides, which she calls the cement that holds the skin cells intact to keep moisture in. One of her go-tos is Eucerin Eczema Care, $9.50, cvs.com. And if you have an episode that doesnt clear, dont sufferhead to your dermatologist to discuss your prescription options.

The combination of falls crisp, brisk edge, blustery winds, and dry indoor heater air can do a number on your skin. Explains Dr. Zeichner, Cold weather and low humidity put a strain on the skin, stripping essential oils needed to maintain hydration. This translates to microscopic cracks in the outer layer, with loss of hydration, dryness, and inflammation. Ouch. Heres how to prevent that from happening, especially if you have psoriasis.

Moisturize intelligently. Cool, dry air calls for richer moisturizer formulasespecially in the face of irritating masks that many of us wear for protection against COVID-19. As the weather gets less humid, it will be especially important to keep your skin moisturized underneath it, says Dr. Goldbach. That means switching to a heavier nighttime moisturizer before bed to help restore the skin barrier while you sleep. But for those who need even more of an assist, Dr. Zeichner recommends putting a hydrating serum on before your hydrating cream, which will add another boost of moisture. Think of it as layering like you would with clothes. One to try: Isdinceutics Hyaluronic Booster, $39, isdn.com.

Prepare for wind. Fall in much of the northern U.S. is known for its blustery days, which can wreak havoc. In fact, one study in the Journal of Society of Cosmetic Chemists of Japan showed that not only does wind exposure decrease hydration but it also slows the replacement of the sebum level after. And on exceptionally windy days, theres the chance of windburn, a sunburn-like condition caused by a combination of dry air, wind friction, and UV exposure.

What to do? Dr. Zeichner says, My best recommendation is to apply a moisturizer right before going outsidethink of it as your base layer. Physical protection from the environment is helpful too, be it a scarf or even your face maskboth will prevent wind from directly irritating the skin. However, make sure to avoid scratchy fabrics like wool, which can not only be rough on skin but can trigger a flare-up of chronic conditions like eczema and psoriasis.

Try a humidifier. One of the things doctors stress for chronic skin diseases: preventing dryness before it starts. Enter a humidifier which adds moisture to the air, helping to head off winter irritation. The gadgets, according to Dr. Zeichner, can be used all year long if needed, but I typically recommend using one starting in the fall when the temperature starts to drop.

His advice: Stick to a cool-mist humidifier, like Honeywell Cool Moisture Germ-Free Humidifier HCM-350, $62, walmart.com. They are as effective as hot steam ones but are safer because they will not burn the skin if you get too close.

Remember balm. Your lips are very sensitivethey can be the first thing to show dryness or even vitamin deficiencies, says Dr. St. Surin-Lord. And with the dry air, that means you can not only be looking at parched lips but potentially an increase in chronic lip conditions like chelitis (caused by lip licking) or cold sores for those who get them, all thanks to your old friend irritation. Thats why its extra important to keep them hydrated as the seasons change. She recommends a lip balm with SPF 30 like Aquaphor Lip Repair, $4, ulta.com, for everyone but especially for anyone who likes to participate in outdoor fall activities like golf, fishing, and biking, as she reminds that lips are vulnerable to skin cancer.

Take care of hands. Parched palms and fingers are always a fall worry, but now with all the extra hand-washing that should be happening across the board, Dr. Goldbach explains that they tend to get dryer than other parts of the body because they are chronically exposed to environmental trauma. That means gloves will help when you leave the house by offering protection. And remember to reach for your favorite hand cream immediately after every washing, which, according to a study in BMC Dermatology, significantly decreases skin roughness after repeated sudsing sessions.

Dont forget the rest. The skin on your body needs a little extra love in the fall, too. Dr. St. Surin-Lord says its all about the formula you use. Lotions are light and good enough to use during the summer and late spring, but during the colder months, I recommend creams and even ointments for extra dry skin. Experiencing flakes? She recommends a moisturizer with an alpha hydroxy acid to add a bit of exfoliation for those dead skin cells. Her pick for all skin types (including reactive chronic conditions like psoriasis): CeraVe Psoriasis Moisturizing Cream With Salicylic acid , $26, cvs.com (although she notes that sal acid is a derivative of aspirin for those who are allergic).

Many people pack away the sunscreen when summer ends, but UV rays in the fall and winter can be just as damaging as they are in the warmer months. Even when the sun doesnt feel warm, it can damage your skin, upping the chances of melanoma and premature aging, even on cloudy days. Heres how to stay sun-smart all season.

Try a physical blocker. In 2019, the FDA suggested more research needs to be done into the impact of chemical sunscreens like oxybenzone when absorbed into the bloodstream. In the meantime, many dermatologists like Dr. St. Surin-Lord recommend mineral sunscreensespecially for those with sensitive skin. Dr. Zeichner agrees and points out that its also a great chance to get in some high-quality skincare ingredients to help replace any of that summer glow you might be missing right now. His pick: Ghost Democracy's Invisible Lightweight Daily Face Sunscreen SPF 33, which, he explains, contains niacinamide, which helps with tone and texture, and turmeric and artichoke leaf extracts, which are rich in antioxidants.

Check the expiration date. Sunscreen formulas have a shelf life of three years, and it can be easy to forget exactly when you acquired each bottle. Thats why at the change of every season Dr. St. Surin-Lord reminds her patients to check the expiration date to make sure they havent gone past the point in which the ingredients are at their full strength. What an awful experience it would be to mow the lawn, garden, or hang out in the park thinking youre safe with expired sunscreen on!

Follow the rules. You know how you know to apply sunscreen 30 minutes before heading outside and then reapplying every two hours in the summer? Dr. St. Surin-Lord insists the same goes for the winter. Since the sun isnt quite top of mind as it is in the summer, it can be easy to forget!

Beware the glare. Late in the season as snow starts to fall in some parts of the country, theres an extra element to toss into your sun-protection consideration: bounce back. If you are shoveling snow or skiing, you should wear sunscreen as the sun reflects on the snow and to your skin, causing sunburns, says Dr. St. Surin-Lord. That, she insists, is a job for SPF 50.

See the original post here:
How to Switch Over Your Skincare Routine for Fall and Winter - HealthCentral.com

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces it will feature the Pharos excimer laser at the New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium 2020 Virtual Meeting being held November 21, 2020.

We are delighted to showcase our Pharos excimer laser at this conference, said Will McGuire, Ra Medical Systems CEO. Pharos provides topical treatment of common skin disorders including psoriasis, vitiligo, atopic dermatitis and leukoderma and is a lower cost and safe alternative to immunosuppressive agents. During the pandemic, Pharos may play a particularly valuable role for patients who may be otherwise immunocompromised.

About the New Frontiers in Cosmetic Medicine & Medical Dermatology Conference

New Frontiers in Cosmetic Medicine Symposium will deal with the latest developments in cosmetic dermatology, cosmetic medicine, and anti-aging medicine. It is designed for an audience of physicians, physician assistants, nurses and nurse practitioners who work under the direct supervision of dermatologists, facial plastic surgeons, oculoplastic surgeons, and plastic surgeons, and commonly assist with cosmetic surgery and medicine. More information is available at https://www.cosmeticfrontiers.com/.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017 the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medicals core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medicals future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as may, will, should, expects, plans, anticipates, could, intends, target, projects, contemplates, believes, estimates, predicts, potential or continue or the negative of these words or other similar terms or expressions that concern Ra Medicals future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and potential outcome of the DABRA atherectomy clinical study. Ra Medicals expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks associated with acceptance of DABRA and Pharos and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products or product enhancements; clinical and statistical verification of the benefits achieved via the use of Ra Medicals products; the results from our clinical trials, which may not support intended indications or may require Ra Medical to conduct additional clinical trials or modify ongoing clinical trials; challenges related to commencement, patient enrollment, completion, and analysis of clinical trials; Ra Medicals ability to manage operating expenses; Ra Medicals ability to effectively manage inventory; Ra Medicals ability to recruit and retain management and key personnel; Ra Medicals need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medicals industry; the impact of rapid technological change; costs and adverse results in any ongoing or future legal proceedings; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medicals news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medicals business and operating results is contained in Ra Medicals Annual Report on Form 10-K for the year ended December 31, 2020 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material information to the public about the company through a variety of means, including our website (www.ramed.com), our investor relations website (https://ir.ramed.com/), press releases, SEC filings, and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Follow this link:
Ra Medical Systems to Feature the Pharos Optimized Excimer Laser at the Virtual New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium...

Psoriatic arthritis and psoriasis have high economic burdens and the total annual costs were similar between the 2 diseases, but the combination of both yielded the highest costs, according to an abstract published at the European League Against Rheumatism annual meeting.

The researchers analyzed 318 patients with psoriasis (n = 196), PsA (n = 43), or both (n = 79) in the COEPSO (Evaluation of Costs in patients with Psoriatic Disease) trial, an observational, retrospective, cross-sectional study in 22 Spanish centers from February 2017 to February 2018.

The authors obtained information from the year prior to the study on direct nonhealth care services (including social services, home care, and private health and nonhealth professionals), as well as indirect and total costs (direct nonhealth care and indirect costs) related to the disease. They calculated out-of-pocket costs, which were specified directly by the patients, and loss of productivity costs, which were gauged by the average salaries for the occupation specific by the patients.

Patients with both psoriasis and PsA had higher annual total costs than patients who only had 1 disease (75.5% higher than patients with psoriasis and 60.9% higher than patients with PsA). However, the total costs for patients with psoriasis and PsA were similar.

The average annual total cost per patient was 1042.71 ($1186.64) for psoriasis, 1137.84 ($1294.90) for PsA, and 1830.26 ($2082.89) for both. The breakdown of direct nonhealth care costs vs indirect costs were:

PsA and [psoriasis] have proved to be diseases with a high economic burden, and the total costs were mainly driven by direct non-healthcare costs, the authors concluded.

Reference

Vincente E, Castaeda S, Llamas Velasco M, et al. Cost of illness in patients with psoriasis and psoriatic arthritis. COEPSO Study. Presented at: EULAR 2020; June 3-6, 2020; Abstract OP0262-HPR. https://ard.bmj.com/content/79/Suppl_1/164.2

Read the original post:
Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis - AJMC.com Managed Markets Network

The global Psoriasis market focuses on encompassing major statistical evidence for the Psoriasis industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Psoriasis study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Psoriasis industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Psoriasis market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Psoriasis report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Psoriasis market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Psoriasis Market report @ https://hongchunresearch.com/request-a-sample/40648

Key players in the global Psoriasis market covered in Chapter 4:, Celgene Corporation, Takeda Pharmaceutical Company Limited, Pfizer Inc., Stiefel Laboratories Inc., Amgen Inc., Biogen Idec, Novartis AG, Eli Lilly and Company, Johnson and Johnson (Janssen Biotech Inc.), AbbVie Inc.

In Chapter 11 and 13.3, on the basis of types, the Psoriasis market from 2015 to 2026 is primarily split into:, Systemic, Phototherapy, Topical Treatment, Others

In Chapter 12 and 13.4, on the basis of applications, the Psoriasis market from 2015 to 2026 covers:, Injectable, Tropical, Oral

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Psoriasis market study further highlights the segmentation of the Psoriasis industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Psoriasis report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Psoriasis market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Psoriasis market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Psoriasis industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Psoriasis Market Report with [emailprotected] https://hongchunresearch.com/report/psoriasis-market-40648

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Psoriasis Market

Chapter Four: Players Profiles

Chapter Five: Global Psoriasis Market Analysis by Regions

Chapter Six: North America Psoriasis Market Analysis by Countries

Chapter Seven: Europe Psoriasis Market Analysis by Countries

Chapter Eight: Asia-Pacific Psoriasis Market Analysis by Countries

Chapter Nine: Middle East and Africa Psoriasis Market Analysis by Countries

Chapter Ten: South America Psoriasis Market Analysis by Countries

Chapter Eleven: Global Psoriasis Market Segment by Types

Chapter Twelve: Global Psoriasis Market Segment by Applications12.1 Global Psoriasis Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Psoriasis Sales and Market Share by Applications (2015-2020)12.1.2 Global Psoriasis Revenue and Market Share by Applications (2015-2020)12.2 Injectable Sales, Revenue and Growth Rate (2015-2020)12.3 Tropical Sales, Revenue and Growth Rate (2015-2020)12.4 Oral Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Psoriasis Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/40648

List of tablesList of Tables and FiguresTable Global Psoriasis Market Size Growth Rate by Type (2020-2026)Figure Global Psoriasis Market Share by Type in 2019 & 2026Figure Systemic FeaturesFigure Phototherapy FeaturesFigure Topical Treatment FeaturesFigure Others FeaturesTable Global Psoriasis Market Size Growth by Application (2020-2026)Figure Global Psoriasis Market Share by Application in 2019 & 2026Figure Injectable DescriptionFigure Tropical DescriptionFigure Oral DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Psoriasis Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Psoriasis Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of PsoriasisFigure Production Process of PsoriasisFigure Manufacturing Cost Structure of PsoriasisFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Celgene Corporation ProfileTable Celgene Corporation Production, Value, Price, Gross Margin 2015-2020Table Takeda Pharmaceutical Company Limited ProfileTable Takeda Pharmaceutical Company Limited Production, Value, Price, Gross Margin 2015-2020Table Pfizer Inc. ProfileTable Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020Table Stiefel Laboratories Inc. ProfileTable Stiefel Laboratories Inc. Production, Value, Price, Gross Margin 2015-2020Table Amgen Inc. ProfileTable Amgen Inc. Production, Value, Price, Gross Margin 2015-2020Table Biogen Idec ProfileTable Biogen Idec Production, Value, Price, Gross Margin 2015-2020Table Novartis AG ProfileTable Novartis AG Production, Value, Price, Gross Margin 2015-2020Table Eli Lilly and Company ProfileTable Eli Lilly and Company Production, Value, Price, Gross Margin 2015-2020Table Johnson and Johnson (Janssen Biotech Inc.) ProfileTable Johnson and Johnson (Janssen Biotech Inc.) Production, Value, Price, Gross Margin 2015-2020Table AbbVie Inc. ProfileTable AbbVie Inc. Production, Value, Price, Gross Margin 2015-2020Figure Global Psoriasis Sales and Growth Rate (2015-2020)Figure Global Psoriasis Revenue ($) and Growth (2015-2020)Table Global Psoriasis Sales by Regions (2015-2020)Table Global Psoriasis Sales Market Share by Regions (2015-2020)Table Global Psoriasis Revenue ($) by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions in 2015Table Global Psoriasis Revenue Market Share by Regions in 2019Figure North America Psoriasis Sales and Growth Rate (2015-2020)Figure Europe Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Sales and Growth Rate (2015-2020)Figure South America Psoriasis Sales and Growth Rate (2015-2020)Figure North America Psoriasis Revenue ($) and Growth (2015-2020)Table North America Psoriasis Sales by Countries (2015-2020)Table North America Psoriasis Sales Market Share by Countries (2015-2020)Figure North America Psoriasis Sales Market Share by Countries in 2015Figure North America Psoriasis Sales Market Share by Countries in 2019Table North America Psoriasis Revenue ($) by Countries (2015-2020)Table North America Psoriasis Revenue Market Share by Countries (2015-2020)Figure North America Psoriasis Revenue Market Share by Countries in 2015Figure North America Psoriasis Revenue Market Share by Countries in 2019Figure United States Psoriasis Sales and Growth Rate (2015-2020)Figure Canada Psoriasis Sales and Growth Rate (2015-2020)Figure Mexico Psoriasis Sales and Growth (2015-2020)Figure Europe Psoriasis Revenue ($) Growth (2015-2020)Table Europe Psoriasis Sales by Countries (2015-2020)Table Europe Psoriasis Sales Market Share by Countries (2015-2020)Figure Europe Psoriasis Sales Market Share by Countries in 2015Figure Europe Psoriasis Sales Market Share by Countries in 2019Table Europe Psoriasis Revenue ($) by Countries (2015-2020)Table Europe Psoriasis Revenue Market Share by Countries (2015-2020)Figure Europe Psoriasis Revenue Market Share by Countries in 2015Figure Europe Psoriasis Revenue Market Share by Countries in 2019Figure Germany Psoriasis Sales and Growth Rate (2015-2020)Figure UK Psoriasis Sales and Growth Rate (2015-2020)Figure France Psoriasis Sales and Growth Rate (2015-2020)Figure Italy Psoriasis Sales and Growth Rate (2015-2020)Figure Spain Psoriasis Sales and Growth Rate (2015-2020)Figure Russia Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Revenue ($) and Growth (2015-2020)Table Asia-Pacific Psoriasis Sales by Countries (2015-2020)Table Asia-Pacific Psoriasis Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2019Table Asia-Pacific Psoriasis Revenue ($) by Countries (2015-2020)Table Asia-Pacific Psoriasis Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2019Figure China Psoriasis Sales and Growth Rate (2015-2020)Figure Japan Psoriasis Sales and Growth Rate (2015-2020)Figure South Korea Psoriasis Sales and Growth Rate (2015-2020)Figure Australia Psoriasis Sales and Growth Rate (2015-2020)Figure India Psoriasis Sales and Growth Rate (2015-2020)Figure Southeast Asia Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Go here to see the original:
Analyzing Impacts Of COVID-19 On Psoriasis Market Effects, Aftermath And Forecast To 2026 - Cole of Duty

The story so far: On July 11, pharma major Biocon announced that it had received the approval of the Drugs Controller General of India (DCGI) to market Itolizumab for treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome patients due to COVID-19. Itolizumab is a monoclonal antibody which is used to treat acute psoriasis.

Monoclonal antibodies are proteins cloned in the lab to mimic antibodies produced by the immune system to counter an infection. They have their genesis in serum, the colourless constituent of blood that contains antibodies. These proteins bind to an antigen, the fragment of an infectious virus in the case of SARS-CoV-2, and either destroy it or block its action. In the case of COVID-19, there are yet no proven drugs to treat moderate or severe manifestations of the disease. Among the therapies being tested is convalescent plasma, which is a constituent of blood and recovered from those who have successfully fought the disease. This blood contains antibodies produced within a week or two of being infected. While plasma therapy involves injecting this entire antibody-soup into another sick patient, a monoclonal antibody can be made by isolating specific antibodies and multiplying them via various techniques. Isolating plasma and serum is laborious and time-consuming when it must be administered to every patient. However, since 1975, several techniques have been perfected that allow antibodies once isolated to be easily replicated. These are stored in vials and can be injected into patients.

Also read | Biocons COVID-19 drug tested on too few patients to reliably conclude on benefits, say experts

While eight in 10 of those infected by the disease recover with little more than a few days of cough and fever, about one in 10 can manifest severe systems of the disease irrespective of their age and medical history. Experts are not sure why, but have observed that many who died were victims of a cytokine storm when the immune system goes into overdrive to flush out the virus. Pro-inflammatory cytokines recruit a host of specialised immune system cells to neutralise antigens. However, these cytokines can aggravate inflammation and injury in lung cells as well as in several other organs. A challenge in treatment is how to prevent this over-reaction. One method is to use antibodies that can block a particular protein, called CD6. They are found on the surface of T-cells, a class of cells that are a central prong in the bodys defence system.

Experts say if this CD-6 is suppressed, it will prevent the T-cells from releasing a cytokine cascade and thus better regulate the immune system. There is also a lot of research going on in using such antibodies to prevent the replication of the virus. Since last month there have been reports from laboratories from nearly everywhere, reporting the presence of one or more antibodies that could be used to block the spike protein, the key the coronavirus uses to infiltrate lung cells and proliferate. Before monoclonal antibodies were roped into discussions surrounding COVID-19, research has focused on deriving the right kind of antibodies that specifically bind onto regions of interest. These underpin the design of cancer therapies or fixes for autoimmune diseases, rheumatoid arthritis or acute psoriasis.

Sometimes antibodies are known to help viral entry and replication in target cells which can worsen the disease. This is why they need careful evaluation.

Also read | No evidence yet that itolizumab, tocilizumab reduces deaths: ICMR head

Itolizumab is an approved drug for acute psoriasis since 2013 and has passed safety and efficacy trials for that disease in over 500 patients. However, independent experts have pointed out that the efficacy of the drug in treating COVID-caused Acute Respiratory Disease Syndrome has not been conclusively demonstrated because it has, as part of a clinical trial, only been tested on 30 patients. However, the drug has been approved by the DCGI for emergency use in the treatment of moderate to severely-ill patients as per the discretion of physicians. The DCGI also directed Biocon to conduct a phase-4 study it must monitor it for adverse reactions or side-effects after it has been administered in large groups of patients and report back to the authorities. Experts pointed out that the normal process for approving a drug includes a phase-3 trial, where the drugs safety and efficacy are first evaluated in the wider population. Officials at Biocon claim they plan to test the drug in the United States, Canada, Australia and New Zealand. Several doctors, at a press conference organised by Biocon, said their patients had benefitted from the drug but mostly when they were yet to reach a stage before requiring ventilators or external oxygen support. The drug cost a little under 8,000 for every vial. Generally, four vials are necessary for treatment, company officials said.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

See the original post here:
The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients? - The Hindu

This article was originally published here

Dermatol Ther. 2020 Jun 17:e13858. doi: 10.1111/dth.13858. Online ahead of print.

ABSTRACT

Coronavirus disease (COVID-19) is a highly contagious respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 outbreak has been declared a pandemic by the World Health Organization on March 2020. The pandemic has affected the management of psoriasis not only for those who are under treatment but also for those who are about to begin a new therapy to control their disease. An increasing number of studies in the current literature have focused on the relationship between psoriasis and COVID-19 from different perspectives. This narrative review includes searching the PubMed and Web of Science databases using the keywords psoriasis, psoriatic arthritis, coronavirus, COVID-19, and SARS-CoV-2. The search was supplemented by manual searching of reference lists of included articles. A total of 11 relevant original investigations and 6 case studies was identified. The search was updated in May 2019. Due to the absence of randomized controlled trials, it is not likely to have a robust evidence-based approach to psoriasis management in the era of COVID-19. However, the current literature may provide some clues for safety considerations. Conventional immunosuppressive therapies such as methotrexate and cyclosporine, and anti-tumor necrosis factor agents should not be preferred due to increased risk of infection, especially in high-risk areas. The use of cyclosporine may pose additional risk due to the side effect of hypertension, which has been reported to be associated with susceptibility to severe COVID-19. Considering that the current literature has provided no conclusive evidence that biologics increase the risk of COVID-19, withdrawal of these agents should be reserved for patients with COVID-19 symptoms. The treatment approach should be personalized, considering the advantages and disadvantages for each case separately.

PMID:32686245 | DOI:10.1111/dth.13858

See the rest here:
Psoriasis and COVID-19: A narrative review with treatment considerations - DocWire News

HELLERUP, Denmark, July 21, 2020 /PRNewswire/ -- UNION therapeutics A/S ("UNION") today announced the completion of a transaction with LEO Pharma A/S (LEO Pharma) to acquire the global rights for the LEO PDE4 inhibitor compound series to be re-named UNI500.

UNI500 is a series of phosphodiesterase type 4 (PDE4) inhibitors that were discovered by LEO Pharma. LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo in randomized, double-blinded, placebo-controlled clinical studies.

"The acquisition of the PDE4 inhibitor compound series is perfectly aligned with UNION's vision to build a sustainable pharmaceutical company and it complements our current clinical activities in immuno-dermatology. The acquisition substantially accelerates our growth trajectory and enables synergies at organizational, financial, and commercial levels. Above and beyond that, UNION considers compounds from the PDE4 inhibitor compound series to have best-in-class potential for the treatment of psoriasis and other immune-dermatological disorders, with an overarching aim to address unmet medical needs", said Rasmus Toft-Kehler, Chief Executive Officer of UNION.

Morten Sommer, Chief Scientific Officer, of UNION explains "Orismilast has demonstrated promising effects in clinical studies suggesting that it could become an attractive oral treatment option for patients with psoriasis and other immune-dermatological disorders. Our ambition, based on demonstrated potency levels, is to develop orismilast as a best-in-class PDE4 inhibitor across multiple immune-related diseases. As a next step, UNION will finalize formulation efforts with orismilast and simultaneously evaluate priority indications for clinical advancement".

Thorsten Thormann, Vice President, Global Research at LEO Pharma added "LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options".

Under the agreement, UNION will pay upfront, development and commercial milestones of up to 200 million USD, plus low single-digit royalties on sales. As part of the transaction, LEO Pharma also becomes a minority shareholder in UNION therapeutics.

About UNION therapeutics A/SUNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and USA.

About LEO Pharma A/SThe company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

ContactsMorten BoesenChief Financial OfficerTel: +45 2381 5487Email: info@uniontherapeutics.com

JW CommunicationsJulia WilsonTel: +44 781 8430877Email: communications@uniontherapeutics.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-acquisition-of-pde4i-compound-class-from-leo-pharma-with-oral-lead-cand,c3157569

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/union-therapeutics-announces-acquisition-of-pde4i-compound-class-from-leo-pharma-with-oral-lead-candidate-orismilast-in-phase-2-301096733.html

SOURCE UNION therapeutics

Read more from the original source:
UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 - BioSpace

Written by Anuradha Mascarenhas | Pune | Updated: July 21, 2020 7:33:30 am The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. (Express Photo/Praveen Khanna)

A repurposed drug, Itolizumab, is one of the newest treatments for Covid-19 approved in India. The Drug Controller General of India recently approved it as a novel biologic therapy for restricted emergency use. The decision has also sparked controversy because of the small size of the clinical trials, and because exemption has been granted from phase-III trials.

Itolizumab is an existing drug used for psoriasis, a chronic skin disease involving unregulated growth of some skin cells that develop into red patches mostly on knees and elbows, but also on some other parts of the body. The drug, developed by Bengaluru-based Biocon, was approved in 2013. It is considered safe and effective for the treatment of psoriasis.

Why was it approved for emergency use in Covid treatment?

The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.

The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. The study focused on the safety and efficacy of Itolizumab in preventing cardio-renal complications in Covid-19 patients who also have acute respiratory distress. The drug has been found to reduce these complications in such patients.

Also in Explained | Why community transmission no longer matters at this stage

Basically, the drug controls the hyper-activation of the immune system in response to SARS-CoV-2 virus and prevents morbidity and mortality related to the cytokine storm. The clinical trial showed that the drug is best administered in the pulmonary phase of the Covid-19 infection when the cytokine build up is starting and the patient is experiencing shortness of breath and exhibiting abnormal chest images. It prevents progression to the hyperinflammation phase (cytokine storm) and other complications like coagulation and organ failure, according to Dr Sandeep Athalye, Chief Medical Officer, Biocon Biologics.

The drug has been used over 80 patients in Cuba and off-label in over 150 cases. According to Dr Shashank Joshi, Dean, Indian College of Physicians, the most critical part is to know when to use the drug and it must be reserved for moderate to severe Covid cases with cytokine storm where oxygen requirements are rapidly going up. usually between the 8th day onwards of Covid infection.

What were the results of the trial?

The trial results showed a statistically significant advantage over the control group of patients, in one-month mortality rate. All the patients who were administered Itolizumab were weaned off oxygen by Day 30, and none needed ventilator support unlike the control group that did not get the drug. Some other inflammations commonly found in such patients were also suppressed, and these correlated well with clinical improvement in symptoms. Overall, the drug was found well-tolerated.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

How large was the trial?

The trial had 20 participants given the drug along with supportive care and 10 others given only supportive care. All 20 patients on Itolizumab recovered while three of the other 10 patients died.

Public health experts and some doctors have used social media to question the sample size of the trial. When journalists raised this question at a virtual press conference, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said Itolizumab has been approved in India and since the country is in a medical emergency, it was decided to go ahead with a clinical trial involving a cohort of 30 patients. She said the regulatory process was extremely robust and the scientific discussions on the trial was of a very high order.

The DCGI has also exempted the drug from phase III clinical trials and allowed phase IV trials (post-marketing surveillance). Itolizumab is not a new drug and was approved in India since 2013. We had done phase II and III trials, and got the approval. In the past seven years, its been used in psoriasis and we know how the mechanism works Biocon Biologics CMO Dr Athalye said. Company officials said they plan phase IV trials soon.

How much does it cost?

Each injection is presented as a 25mg/5ml solution, which costs Rs 7,950 per vial. Based on an average body weight of 60 kg, the therapy cost of a single dose comprising four vials is estimated at Rs 32,000 (MRP).

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Link:
Explained: What is Itolizumab, newly cleared for Covid-19? - The Indian Express